|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5283173A
(en)
|
1990-01-24 |
1994-02-01 |
The Research Foundation Of State University Of New York |
System to detect protein-protein interactions
|
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
GB9115364D0
(en)
|
1991-07-16 |
1991-08-28 |
Wellcome Found |
Antibody
|
|
AU669124B2
(en)
|
1991-09-18 |
1996-05-30 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing humanized chimera antibody
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US6210671B1
(en)
|
1992-12-01 |
2001-04-03 |
Protein Design Labs, Inc. |
Humanized antibodies reactive with L-selectin
|
|
US6180377B1
(en)
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
DK1034298T3
(da)
|
1997-12-05 |
2012-01-30 |
Scripps Research Inst |
Humanisering af murint antistof
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
US6410319B1
(en)
|
1998-10-20 |
2002-06-25 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
|
US6849425B1
(en)
|
1999-10-14 |
2005-02-01 |
Ixsys, Inc. |
Methods of optimizing antibody variable region binding affinity
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
US7514537B2
(en)
|
2001-04-30 |
2009-04-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human gliomas
|
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
US7390885B2
(en)
|
2001-11-26 |
2008-06-24 |
Cell Matrix, Inc. |
Humanized collagen antibodies and related methods
|
|
DK1773884T3
(da)
*
|
2004-08-03 |
2012-05-21 |
Innate Pharma |
Terapeutiske og diagnostiske fremgangsmåder og sammensætninger til targeting af 4ig-b7-h3 og dets tilsvarende nk-celle-receptor
|
|
JP2008527001A
(ja)
|
2005-01-13 |
2008-07-24 |
ザ ジョンズ ホプキンス ユニバーシティー |
前立腺幹細胞抗原ワクチンおよびその使用
|
|
US20090041783A1
(en)
*
|
2005-04-28 |
2009-02-12 |
Mochida Pharmaceutical Co., Ltd. |
Anti-platelet membrane glycoprotein vi monoclonal antibody
|
|
EP2331566B1
(en)
|
2008-08-26 |
2015-10-07 |
City of Hope |
Method and compositions for enhanced anti-tumor effector functioning of t cells
|
|
EP2258719A1
(en)
|
2009-05-19 |
2010-12-08 |
Max-Delbrück-Centrum für Molekulare Medizin (MDC) |
Multiple target T cell receptor
|
|
GB0908816D0
(en)
*
|
2009-05-21 |
2009-07-01 |
Royal Holloway University Of L |
Method
|
|
EP2542256B1
(en)
*
|
2010-03-04 |
2019-05-22 |
MacroGenics, Inc. |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
WO2012147713A1
(ja)
|
2011-04-25 |
2012-11-01 |
第一三共株式会社 |
抗ｂ７－ｈ３抗体
|
|
BR122020002986A8
(pt)
|
2012-08-20 |
2023-04-18 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Método e composições para imunoterapia celular
|
|
US9790282B2
(en)
|
2013-03-25 |
2017-10-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
|
|
AU2014317009A1
(en)
*
|
2013-09-05 |
2016-03-10 |
Aduro Biotech Holdings, Europe B.V. |
CD70-binding peptides and method, process and use relating thereto
|
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
EP3149040A1
(en)
*
|
2014-05-29 |
2017-04-05 |
Spring Bioscience Corporation |
Anti-b7-h3 antibodies and diagnostic uses thereof
|
|
US10562952B2
(en)
|
2015-09-10 |
2020-02-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD276 chimeric antigen receptors
|
|
BR112018006817A2
(pt)
*
|
2015-10-08 |
2018-10-23 |
Macrogenics Inc |
método de tratamento do câncer
|
|
GEP20227398B
(en)
*
|
2016-04-15 |
2022-07-25 |
Macrogenics Inc |
Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
AU2017279550A1
(en)
|
2016-06-08 |
2019-01-03 |
Abbvie Inc. |
Anti-B7-H3 antibodies and antibody drug conjugates
|
|
WO2018013611A1
(en)
*
|
2016-07-11 |
2018-01-18 |
Corvus Pharmaceuticals, Inc. |
Anti-cd73 antibodies
|
|
AU2017302668B9
(en)
|
2016-07-28 |
2023-06-22 |
Novartis Ag |
Combination therapies of chimeric antigen receptors and PD-1 inhibitors
|
|
MX2019011117A
(es)
*
|
2017-03-31 |
2019-11-05 |
Jiangsu Hengrui Medicine Co |
Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
|